DPCO LIST- Rishab Healthcare

LATEST DPCO NOTIFICATION

 

                                                               

New Delhi, the 17th August, 2016

ORDER

S.O.2729(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Ritonavir Tablet Ritonavir-100mg 1 Tablet 26.92
2 Primaquine Tablet Primaquine-15mg 1 Tablet 4.26
3 Efavirenz Tablet Efavirenz-600mg 1 Tablet 63.19

NOTE :

(a)        All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.

(b)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(e)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(h)        Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/167/35/2016/F

 

New Delhi, the 17th August, 2016

ORDER

S.O.2730(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Atropine Injection Atropine-0.6mg/ml 1 ml 3.73
2 Ibuprofen Tablet Ibuprofen-200mg 1 Tablet 0.35
3 Ibuprofen Tablet Ibuprofen-400mg 1 Tablet 0.65
4 Neostigmine Injection Neostigmine-0.5mg/ml 1 ml 4.04
5 Carbamazepine Oral Liquid Carbamazepine-100mg/5ml 1 ml 0.18
6 Diazepam Suppository Diazepam-5mg 1 Suppository 5.54
7 Phenobarbitone Injection Phenobarbitone-200mg/ml 1 ml 17.78
8 Nitrofurantoin Tablet Nitrofurantoin-100mg 1 Tablet 6.71
9 Rifampicin Capsule Rifampicin-150mg 1 Capsule 1.82
10 Rifampicin Capsule Rifampicin-300mg 1 Capsule 3.37
11 Rifampicin Capsule Rifampicin-450mg 1 Capsule 4.43
12 Primaquine Tablet Primaquine-7.5mg 1 Tablet 1.96
13 Imatinib Mesylate Tablet Imatinib Mesylate-100mg 1 Tablet 71.66
14 Procarbazine Capsule Procarbazine-50mg 1 Capsule 30.76
15 Tamoxifen Tablet Tamoxifen-10mg 1 Tablet 2.39
16 Tamoxifen Tablet Tamoxifen-20mg 1 Tablet 2.70
17 Misoprostol Tablet Misoprostol-100mcg 1 Tablet 8.08
18 Salbutamol Tablet Salbutamol-2mg 1 Tablet 0.14838

NOTE :

(a)        All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.

(b)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(e)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(h)        Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/167/35/2016/F

 

New Delhi, the 17th August, 2016

ORDER

S.O.2732(E)  – In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No. Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer & Marketing Company respectively Retail Price (Rs.)
(1) (2) (3) (4) (5) (6)
1 Amlodipine +
Metoprolol Tablet
(Starpress-AM XL 25)
Each uncoated bilayerd tablet contains:
Amlodipine Besylate eq. to
Amlodipine-5mg
Metoprolol Succinate-23.75mg eq. to
Metoprolol Tartrate-25mg
(as extended release form)
1 Tablet M/s Tristar Formulations Pvt. Ltd. &
M/s Lupin Ltd.
4.80
2 Amlodipine +
Metoprolol Tablet
(Amlodac M25)
Each uncoated bilayered tablet contains:
Amlodipine Besylate eq. to
Amlodipine-5mg
Metoprolol Succinate-23.75mg eq. to
Metoprolol Tartrate-25mg
(as extended release)
1 Tablet M/s German Remedies Ltd. 4.80
3 Glimepiride Tablet
(Glucoryl 4mg)
Each film coated tablet contains:
Glimepiride-4mg
1 Tablet M/s Savi Pharma &
M/s Alkem Lab. Ltd.
6.00
4 r-Hu Erythropoietin
(r-HuEPO) Injection
(Renocrit 4000)
Each pre-filled syringe contains:
r-Hu Erythropoietin (r-HuEPO)-4000 IU
Each Pack M/s Cadila Healthcare Ltd. 1237.23
5 Zoledronic Acid infusion Each 100ml contains:
Zoledronic Acid-4mg
Each Pack M/s Cadila Healthcare Ltd. 3609.13
6 Doxorubicin HCl Pegylated
Liposomal Injection
Each ml contains:
Doxorubicin HCl Pegylated Liposomal-2mg
1 ml M/s Emcure Pharmaceuticals Ltd. 723.93
7 Telmisartan+
Chlorthalidone Tablet
Each uncoated bilayered tablet contains:
Telmisartan-40mg
Chlorthalidone-6.25mg
1 Tablet M/s Windlas Biotech Ltd. &
M/s Emcure Pharmaceuticals Ltd.
7.73
8 Metformin HCl SR+
Voglibose+
Glimepiride Tablet
Each uncoated bilayered tablet contains:
Metformin HCl-500mg
(in sustained release form)
Voglibose-0.2mg
Glimepiride-2mg
10 Tablets M/s Inventia Healthcare Pvt. Ltd. &
M/s Jubilant Life Sciences Ltd.
90.48
9 Metformin HCl SR+
Voglibose+
Glimepiride Tablet
Each uncoated bilayered tablet contains:
Metformin HCl-500mg
(in sustained release form)
Voglibose-0.2mg
Glimepiride-1mg
10 Tablets M/s Inventia Healthcare Pvt. Ltd. &
M/s Jubilant Life Sciences Ltd.
71.43
10 Paroxetine HCl+
Clonazepam Capsule
(Clonotril P 25mg)
Each hard gelatin capsule contains:
Paroxetine HCl (as Hemihydrate)
eq. to Paroxetine-25mg
(as enteric coated controlled release tablet)
Clonazepam-0.5mg
(as immediate release tablet)
1 Capsule M/s Torrent Pharmaceuticals Ltd. 12.50
11 Paroxetine HCl+
Clonazepam Capsule
(Clonotril P 25mg)
Each hard gelatin capsule contains:
Paroxetine HCl (as Hemihydrate)
eq. to Paroxetine-12.5mg
(as enteric coated controlled release tablet)
Clonazepam-0.5mg
(as immediate release tablet)
1 Capsule M/s Torrent Pharmaceuticals Ltd. 10.27
12 Phenylephrine HCl+
Chlorpheniramine
Maleate+Paracetamol+
Sodium Citrate+
Menthol Syrup
(Sudin Kid +)
Each 5ml contains:
Phenylephrine HCl-5mg
Chlorpheniramine Maleate-0.5mg
Paracetamol-125mg
Sodium Citrate-60mg
Menthol-1mg
1 ml M/s Enicar Pharmaceuticals Pvt. Ltd. &
M/s Group Pharmaceuticals Ltd.
0.59
13 Phenylephrine HCl+
Chlorpheniramine
Maleate+Paracetamol+
Sodium Citrate+
Menthol Syrup
(Nablok-New)
Each 5ml contains:
Phenylephrine HCl-5mg
Chlorpheniramine Maleate-0.5mg
Paracetamol-125mg
Sodium Citrate-60mg
Menthol-1mg
1 ml M/s Pharma Force Lab. &
M/s Lifestar Pharma Pvt. Ltd.
0.59

NOTE :

(a)        The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b)        The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c)        The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.

(d)        The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(e)        The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f)        In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g)        Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.

PN/167/35/2016/F

 

 

New Delhi, the 29th July, 2016

ORDER

S.O.2569(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:I

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Colchicine Tablet Colchicine -0.5mg 1 Tablet 2.88
2 Chlorpheniramine Tablet Chlorpheniramine-4mg 1 Tablet 0.08514
3 Clofazimine Capsule Clofazimine-50mg 1 Capsule 1.28
4 Clofazimine Capsule Clofazimine-100mg 1 Capsule 2.20
5 Ethambutol Tablet Ethambutol-200mg 1 Tablet 0.94
6 Ethambutol Tablet Ethambutol-400mg 1 Tablet 2.14
7 Ethambutol Tablet Ethambutol-600mg 1 Tablet 3.15
8 Pyrazinamide Tablet Pyrazinamide-1500mg 1 Tablet 9.29
9 Fluconazole Tablet Fluconazole-100mg 1 Tablet 7.40
10 Lamivudine +
Zidovudine Tablet
Lamivudine-150mg
Zidovudine-300mg
1 Tablet 18.61
11 Stavudine +
Lamivudine Tablet
Stavudine-30mg
Lamivudine-150mg
1 Tablet 8.86
12 Zidovudine Tablet Zidovudine-300mg 1 Tablet 12.69
13 Chlorambucil Tablet Chlorambucil-2mg 1 Tablet 32.84
14 Cyclophosphamide Tablet Cyclophosphamide-50mg 1 Tablet 3.61
15 Melphalan Tablet Melphalan-2mg 1 Tablet 87.30
16 Melphalan Tablet Melphalan-5mg 1 Tablet 149.73
17 Diazepam Tablet Diazepam-2mg 1 Tablet 1.39
18 Diazepam Tablet Diazepam-5mg 1 Tablet 1.32
19 Metoclopramide Tablet Metoclopramide-10mg 1 Tablet 1.08
20 Glyceryl Trinitrate Sublingual Tablet Glyceryl Trinitrate-0.5 mg 1 Tablet 1.68
21 Atenolol Tablet Atenolol -100 mg 1 Tablet 3.24
22 Ethinylestradiol Tablet Ethinylestradiol-0.01mg 1 Tablet 2.10
23 Acetazolamide Tablet Acetazolamide-250mg 1 Tablet 3.26

NOTE :

(a)        All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.

(b)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(e)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(h)        Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/166/34/2016/F

  1. No. 8(34)/2016/D.P./NPPA-Div.II

(BALJIT SINGH)
Assistant Director
National Pharmaceutical Pricing Authority

 

 

New Delhi, the 29th July, 2016

ORDER

S.O.2568(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Doxycycline Capsule Doxycycline-100mg 1 Capsule 2.32

NOTE :

(a)        All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.

(b)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(e)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(h)        Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/166/34/2016/F

F. No. 8(34)/2016/D.P./NPPA-Div.II

(BALJIT SINGH)
Assistant Director
National Pharmaceutical Pricing Authority

 

 

 

 

Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 23rd June, 2016

ORDER

S.O.2193(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Tramadol Capsule Tramadol-50mg 1 Capsule 4.20
2 Leflunomide Tablet Leflunomide -10 mg 1 Tablet 9.30
3 Leflunomide Tablet Leflunomide -20 mg 1 Tablet 18.13
4 Methotrexate Tablet Methotrexate-10 mg 1 Tablet 10.81
5 Methotrexate Tablet Methotrexate -7.5mg 1 Tablet 10.32
6 Prednisolone Tablet Prednisolone -20mg 1 Tablet 1.81
7 Carbamazepine Tablet Carbamazepine -200 mg 1 Tablet 1.28
8 Phenobarbitone Tablet Phenobarbitone -30mg 1 Tablet 1.12
9 Sodium valproate Tablet Sodium valproate -200mg 1 Tablet 2.75
10 Sodium Valporate Tablet Sodium Valporate-500mg 1 Tablet 6.43
11 Albendazole Tablet Albendazole-400mg 1 Tablet 7.15
12 Diethylcarbamazine Tablet Diethylcarbamazine-50mg 1 Tablet 0.50
13 Metronidazole Tablet Metronidazole-200mg 1 Tablet 0.40
14 Pyrazinamide Tablet Pyrazinamide-500mg 1 Tablet 3.77
15 Pyrazinamide Tablet Pyrazinamide-750mg 1 Tablet 5.73
16 Pyrazinamide Tablet Pyrazinamide-1000mg 1 Tablet 8.39
17 Ethambutol Tablet Ethambutol-800mg 1 Tablet 3.77
18 Fluconazole Tablet Fluconazole-200mg 1 Tablet 17.43
19 Griseofulvin Tablet Griseofulvin-250mg 1 Tablet 1.48
20 Acyclovir Tablet Acyclovir-200mg 1 Tablet 6.29
21 Acyclovir Tablet Acyclovir-400mg 1 Tablet 11.42
22 Quinine Tablet Quinine-300mg 1 Tablet 5.09
23 Mefloquine Tablet Mefloquine-250mg 1 Tablet 47.31
24 Propranolol Tablet Propranolol-10mg 1 Tablet 1.07
25 Methotrexate Tablet Methotrexate-2.5mg 1 Tablet 4.26
26 Cyclosporine Capsule Cyclosporine-50mg 1 Capsule 46.85
27 Cyclosporine Capsule Cyclosporine-100mg 1 Capsule 91.21
28 Ondansetron Tablet Ondansetron-8mg 1 Tablet 9.06
29 Amitriptyline Tablet Amitriptyline-25mg 1 Tablet 2.10
30 Fluoxetine Capsule Fluoxetine-20mg 1 Capsule 3.38
31 Warfarin Tablet Warfarin-5mg 1 Tablet 2.20
32 Diltiazem Tablet Diltiazem -30mg 1 Tablet 2.23
33 Diltiazem Tablet Diltiazem -60mg 1 Tablet 4.53
34 Amiodarone Tablet Amiodarone-100mg 1 Tablet 5.30
35 Amlodipine Tablet Amlodipine-2.5mg 1 Tablet 1.53
36 Atenolol Tablet Atenolol-50mg 1 Tablet 1.66
37 Enalapril Tablet Enalapril-2.5mg 1 Tablet 1.78
38 Enalapril Tablet Enalapril-5mg 1 Tablet 2.97
39 Domperidone Tablet Domperidone-10mg 1 Tablet 2.24
40 Medroxyprogesteroneacetate Tablet Medroxyprogesteroneacetate-10mg 1 Tablet 4.99
41 Nifedipine Tablet Nifedipine -10mg 1 Tablet 1.15
42 Salbutamol Tablet Salbutamol-4mg 1 Tablet 0.17

NOTE :

(a)        All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.

(b)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(e)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Price Control) Order, 2013 read with Essential Commodities Act, 1955.

(h)        Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/165/33/2016/F

 

Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 23rd June, 2016

ORDER

S.O.2194(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1816(E), dated 18th May, 2016 regarding formulation packs mentioned in the table at Sl. No. 20, 21 & 22 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Insulin (Soluble) Injection Insulin (Soluble)-40IU/ml 1 ml 13.40
2 Intermediate Acting (NPH)
Insulin Injection
Intermediate Acting
(NPH) Insulin-40IU/ml
1 ml 13.40
3 Premix Insulin (30:70)
(Regular : NPH) Injection
Premix Insulin (30:70)
(Regular : NPH) -40IU/ml
1 ml 13.40

NOTE :

(a)        All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.

(b)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(e)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(f)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Price Control) Order, 2013 read with Essential Commodities Act, 1955.

(h)        Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/165/33/2016/F

 

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 23rd June, 2016

ORDER

S.O.2195(E)  – In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No. Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer & Marketing Company respectively Retail Price (Rs.)
(1) (2) (3) (4) (5) (6)
1 Diclofenac Sodium Injection
(Volitra AQ)
Each ml contains:
Diclofenac sodium-75mg
1 ml M/s Akums Drugs & Pharmaceuticls Ltd. &
M/s Sun Pharmaceutical Industries Ltd.
14.30
2 Metformin HCl +
Gliclazide Tablet
(Glychek M OD 60)
Each uncoated bilayered
sustained release tablet contains:
Metformin HCl-500mg
(In extended release form)
Gliclazide-60mg
(In modified release form)
1 Tablet M/s Swiss Garnier Genexiaa Sciences &
M/s Indoco Remedies Pvt. Ltd.
7.98
3 Albendazole+
Ivermectin Tablet
(Zenebend Plus)
Each uncoated tablet contains:
Albendazole-400mg
Ivermectin-6mg
1 Tablet M/s Samson Lab. Pvt. Ltd. &
M/s Galpha Lab. Ltd.
15.20
4 Moxifloxacin HCl +
Cefixime Tablet
(Zifi-Max)
Each film coated sustained
release tablet contains:
Moxifloxacin HCl eq. to
Moxifloxacin-400mg
Cefixime (as trihydrate) eq. to
anhydrous cefixime-400mg
1 Tablet M/s Malik Lifescience Pvt. Ltd. &
M/s FDC Ltd.
34.46
5 Dicyclomine HCl Tablet Each uncoated tablet contains:
Dicyclomine HCl-20mg
1 Tablet M/s Meridian Enterprises Pvt. Ltd. 0.85
6 Rabeprazole Sodium+
Domperidone Capsule
Each hard gelatin capsule contains:
Rabeprazole sodium-40mg
(as reddish brown coloured enteric coated pellets)
Domperidone-30mg
(as orange coloured sustained release pellets)
1 Capsule M/s Windlas Biotech Ltd. &
M/s Intas Pharmaceuticals Ltd.
7.19
7 Metformin HCl+
Gliclazide Tablet
(Glychek M OD 30)
Each uncoated bilayered sustained
release tablet contains:
Metformin HCl-500mg
(In extended release form)
Gliclazide-30mg
(In modified release form)
1 Tablet M/s Swiss Garnier Genexiaa Sciences &
M/s Indoco Remedies Pvt. Ltd.
4.96
8 Clindamycin Phosphate +
Hydrous Benzoyl Peroxide Gel
Each gm contains:
Clindamycin Phosphate eq. to
Clindamycin-1% w/v
Hydrous Benzoyl Peroxide eq. to
anhydrous benzoyl Peroxide-2.5% w/w
1 Gram M/s Cadila Pharmaceuticals Ltd. 13.31
9 Telmisartan+
Indapamide Tablet
(Telma D)
Each uncoated bilayered tablets contains:
Telmisartan-40mg
Indapamide-1.5mg
(as sustained release form)
1 Tablet M/s Windlas Biotech Ltd.&
M/s Glenmark Pharmaceuticals Ltd.
8.84
10 Tramadol HCl +
Diclofenac Sodium Tablet
(Dolinsta)
Each film coated bilayered tablet contains:
Tramadol HCl-50mg
Diclofenac Sodium-75mg
(as sustained release form)
1 Tablet M/s Sunglow Pharmaceuticals (P) Ltd. &
M/s Indoco Remedies Pvt. Ltd.
10.08
11 Paracetamol Injection
(Paralup IV)
Each 100ml contains:
Paracetamol-1gm
1 injection (100ml) M/s Eurolife Healthcare Pvt. Ltd. &
M/s Lupin Ltd.
206.00
12 Telmisartan+
Nebivolol HCl Tablet
(Telma NB)
Each uncoated bilayered
tablets contains:
Telmisartan-40mg
Nebivolol HCl eq. to Nebivolol-5mg
1 Tablet M/s Windlas Biotech Ltd.&
M/s Glenmark Pharmaceuticals Ltd.
11.04

NOTE :

(a)        The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b)        The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c)        The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.

(d)        The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(e)        The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f)        In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g)        Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.

PN/165/33/2016/F

 

 

 

LATEST DPCO NOTIFICATION

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 2nd June, 2016

ORDER

S.O.1351(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Diclofenac Tablet Diclofenac-50 mg 1 Tablet 1.77
2 Paracetamol Tablet Paracetamol-500 mg 1 Tablet 0.83
3 Cetirizine Tablet Cetirizine-10 mg 1 Tablet 1.53
4 Phenobarbitone Tablet Phenobarbitone-60mg 1 Tablet 1.64
5 Amoxycillin Capsule Amoxycillin-250mg 1 Capsule 2.05
6 Ceftriaxone Powder For Injection Ceftriaxone -250 mg Each Pack 22.90
7 Amoxicillin+
Clavulanic Acid Oral Liquid
Amoxicillin -200mg+
Clavulanic Acid-28.5mg/5ml
1 ml 1.68
8 Fluconazole Tablet Fluconazole -150mg 1 Tablet 10.99
9 Propranolol Tablet Propranolol-40mg 1 Tablet 2.59
10 Imatinib Tablet Imatinib-400mg 1 Tablet 213.32
11 Azathioprine Tablet Azathioprine-50mg 1 Tablet 9.02
12 Allopurinol Tablet Allopurinol-100mg 1 Tablet 1.76
13 Ondansetron Tablet Ondansetron-4mg 1 Tablet 4.35
14 Ondansetron Injection Ondansetron-2mg/ml 1 ml 5.43
15 Trihexyphenidyl Tablet Trihexyphenidyl-2mg 1 Tablet 1.13
16 Metoprolol Tablet Metoprolol-25mg 1 Tablet 2.88
17 Metoprolol Tablet Metoprolol-50mg 1 Tablet 4.36
18 Pantoprazole Injection Pantoprazole-40mg Each Pack 41.32
19 Hyoscine Butyl Bromide Tablet Hyoscine Butyl Bromide-10mg 1 Tablet 2.77
20 Bisacodyl Tablet Bisacodyl-5mg 1 Tablet 0.93
21 Ethinylestradiol+
Levonorgestrel Tablet
Ethinylestradiol-0.03mg+
Levonorgestrel-0.15mg
1 Tablet 3.07
22 Metformin Immediate Release Tablet Metformin-500mg 1 Tablet 1.39
23 Norethisterone Tablet Norethisterone-5mg 1 Tablet 4.75
24 Carbimazole Tablet Carbimazole-5mg 1 Tablet 1.76
25 Ascorbic Acid (Vitamin C) Tablet Ascorbic Acid (Vitamin C)-500mg 1 Tablet 0.73

NOTE :

(a)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(b)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(c)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per paragraph 24 (2) of the DPCO, 2013.

(d)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Price Control) Order, 2013 read with Essential Commodities Act, 1955.

(g)        Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/164/32/2016/F

 

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 2nd June, 2016

ORDER

S.O.1352(E)  – In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No. Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer & Marketing Company respectively Retail Price (Rs.)
(1) (2) (3) (4) (5) (6)
1 Cefixime +
Ofloxacin Tablet
(Cefaclass – O Tablet)
Each film coated tablet contains:
Cefixime (as trihydrate) eq. to
Anhydrous Cefixime 200mg
Ofloxacin 200mg
1 Tablet M/s Scott Edil Advance Research
Lab. & Education Ltd.&
M/s Gem Mankind
9.86
2 Adapalene +
Benzoyl Peroxide Gel
Each gm contains:
Adapalene 0.1% w/w
Hydrous Benzoyl Peroxide eq. to
Anhydrous Benzoyl Peroxide 2.5% w/w
1 Gram M/s Apex Lab. Pvt. Ltd. 18.10
3 Diclofenac sodium Tablet
(Zeldinac 100 SR)
Each sustained release film coated
tablet contains:
Diclofenac Sodium-100mg
1 Tablet M/s Innova Captab &
M/s Leeford Healthcare Ltd.
4.28
4 Gliclazide+
Metformin HCl Tablet
(Azukon M OD 30)
Each uncoated bilayered tablet contains:
Gliclazide (as extended release)-30mg
Metformin HCl (as extended release)-500mg
1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. &
M/s Torrent Pharmaceuticals Ltd.
4.96
5 Gliclazide+
Metformin HCl Tablet
(Azukon M OD 60)
Each uncoated bilayered tablet contains:
Gliclazide (as extended release)-60mg
Metformin HCl (as extended release)-500mg
1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. &
M/s Torrent Pharmaceuticals Ltd.
7.98
6 Dextromethorphan Hydrobromide +
Chlorpheniramine Maleate syrup
Each 5ml contains:
Dextromethorphan Hydrobromide 10mg
Chlorpheniramine Maleate 2mg
1 ml M/s Apex Lab. Pvt. Ltd. 0.50
7 Paclitaxel (Protein bound particle)
for Injectable Suspension
Each vial contains:
Paclitaxel 100mg
Human Albumin
1 Vial M/s Beta Drugs Pvt. Ltd. &
M/s Cadila Pharmaceuticals Ltd.
11590.00
8 Escitalopram Oxalate +
Clonazepam Tablet
(Megapose-Plus New)
Each film coated tablet contains:
Escitalopram Oxalate eq. to Escitalopram 10mg
Clonazepam 0.5mg
1 Tablet M/s Windlas Biotech Ltd. &
M/s Magnet Labs. Pvt. Ltd.
8.62

NOTE :

(a)        The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b)        The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c)        The retail price for a pack of the aforesaid formulations shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V as per paragraph 24 (2) of the DPCO, 2013.

(d)        The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(e)        The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f)        In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g)        Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.

PN/164/32/2016/F

DPCO NOTIFICATION    

 

 

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 18th May, 2016

ORDER

S.O.1816(E)  – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No. Name of the Scheduled Formulation Strength Unit Ceiling Price (Rs.)
(1) (2) (3) (4) (5)
1 Hydroxychloroquine Tablet Hydroxychloroquine -200 mg 1 Tablet 5.50
2 Sulfasalazine Tablet Sulfasalazine -500 mg 1 Tablet 3.70
3 Dexamethasone Tablet Dexamethasone -0.5 mg 1 Tablet 0.18
4 Prednisolone Tablet Prednisolone -5mg 1 Tablet 0.52
5 Prednisolone Tablet Prednisolone -10mg 1 Tablet 0.90
6 Phenytoin Phenytoin -100 mg 1 Tablet 1.27
7 Amoxicillin Capsule Amoxicillin -500mg 1 Capsule 5.70
8 Amoxicillin+
Clavulanic Acid Tablet
Amoxicillin -500mg+
Clavulanic Acid-125mg
1 Tablet 16.14
9 Amoxicillin+ Clavulanic Acid
Powder for Injection
Amoxicillin -1gm+
Clavulanic Acid-200mg
Each Pack 113.91
10 Cefixime Tablet Cefixime -200mg 1 Tablet 8.48
11 Metronidazole Tablet Metronidazole -400mg 1 Tablet 0.75
12 Levodopa+
Carbidopa Tablet
Levodopa -100mg+
Carbidopa-25mg
1 Tablet 2.10
13 Levodopa+
Carbidopa Tablet
Levodopa -100mg+
Carbidopa-10mg
1 Tablet 1.44
14 Folic Acid Tablet Folic Acid -5mg 1 Tablet 1.28
15 LAmiodarone Tablet Amiodarone -200mg 1 Tablet 10.51
16 LSodium Nitroprusside Injection Sodium Nitroprusside -10mg/ml 1 ml 23.95
17 Digoxin Tablet Digoxin -0.25mg 1 Tablet 1.11
18 Omeprazole Capsule Omeprazole -20mg 1 Capsule 2.31
19 Oral Rehydration Salts (As Licensed) 1 Gram 0.71
20 Insulin (Soluble) Injection Insulin (Soluble)-40IU/ml 1 ml 13.34
21 Intermediate Acting (NPH)
Insulin Injection
Intermediate Acting
(NPH) Insulin-40IU/ml
1 ml 13.34
22 Premix Insulin (30:70)
(Regular : NPH) Injection
Premix Insulin (30:70)
(Regular : NPH) -40IU/ml
1 ml 13.34
23 Carbimazole Tablet Carbimazole -10mg 1 Tablet 3.42
24 Mifepristone Tablet Mifepristone -200mg 1 Tablet 298.49

NOTE :

(a)        All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(b)        The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(c)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per paragraph 24 (2) of the DPCO, 2013.

(d)        Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(e)        The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Price Control) Order, 2013 read with Essential Commodities Act, 1955.

(g)        Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/163/31/2016/F

  1. No. 8(31)/2016/D.P./NPPA-Div.II

Latest DPCO list 2016

To View in pdf Format click the link below

ClICK HERE

 

 

                          RETAIL PRICE (NEW DRUGS) FIXED UNDER PARA 5 OF DPCO, 2013.

YEAR : 2016

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

 

 

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

 

 

New Delhi, the 24th February, 2016

 

 

ORDER

 

S.O. 583(E)   In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer and marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl.
No.
Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer and Marketing Company respectively Retail Price (Rs.)
1 2 3 4 5 6
1 Pantoprazole Sodium Tablet
(Mahapanta 40)
Each enteric coated tablet contains:
Pantoprazole Sodium eq. to
Pantoprazole-40mg
1 Tablet M/s Innova Captab and M/s Gem Mankind 5.56
2 Paracetamol Paediatric Oral suspension Each ml contains:
Paracetamol-50mg
1 ml M/s Apex Lab. Pvt. Ltd.

 

0.94
3 Amlodipine Besilate+
Atenolol Tablet
(Atnoblok-AM)
Each uncoated tablet contains:
Amlodipine besilate eq. to
Amlodipine-5mg
Atenolol-50mg
1 Tablet M/s Pharma Force Lab. and M/s Gem Mankind 3.62
4 Amikacin Sulphate+
Methyl Paraben+
Propyl Paraben Injection
(Mikagem-500)
Each 2ml vial contains:
Amikacin sulphate eq. to
Amikacin-500mg
Methyl Paraben-0.08% w/v (as preservative)
Propyl Paraben-0.02% w/v (as preservative)
Water for Injection
Each Pack M/s Scott Edil Pharmacia and M/s Gem Mankind 54.87

 

5 Amikacin Sulphate+
Methyl Paraben+
Propyl Paraben Injection
(Mikagem-100)
Each 2ml vial contains:
Amikacin sulphate eq. to
Amikacin-100mg
Methyl Paraben-0.08% w/v (as preservative)
Propyl Paraben-0.02% w/v (as preservative)
Water for Injection
Each Pack M/s Scott Edil Pharmacia and M/s Gem Mankind 15.98
6 Diclofenac+Linseed Oil+
Methyl Salicylate+
Menthol Gel
Each gm contains:
Diclofenac Diethylamine-1.16% w/w
eq. to Diclofenac Sodium-1% w/w
Linseed Oil-3% w/w
Methyl Salicylate-10% w/w
Menthol-5% w/w
1 Gram M/s Embiotic Lab. Pvt. Ltd.

 

2.11
7 Diclofenac+Linseed Oil+
Methyl Salicylate+
Menthol Gel
Each gm contains:
Diclofenac Diethylamine-1.16% w/w
eq. to Diclofenac Sodium-1% w/w
Linseed Oil-3% w/w
Methyl Salicylate-10% w/w
Menthol-5% w/w
1 Gram M/s Apex Lab. Pvt. Ltd.

 

2.11
8 Methyl Prednisolone Tablet
(Depotex 8)
Each uncoated tablet contains:
Methyl Prednisolone-8mg
1 Tablet M/s Cadila Healthcare Ltd. 4.78
9 Propranolol HCl Tablet
(Inderal LA)
Each uncoated sustained release tablet contains:
Propranolol HCl-80mg
1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. and M/s Abbott Healthcare Pvt. Ltd. 4.81
10 Amoxycillin Trihydrate+
Dicloxacillin Sodium
Capsule
(Mahamox Plus)
Each hard gelatine capsule contains:
Amoxycillin Trihydrate eq. to
Amoxycilline-250mg
Dicloxacillin Sodium eq. to
Dicloxacillin-250mg
1 Capsule M/s Scott Edil Advance Research Lab. & Education Ltd. and M/s Gem Mankind 5.21
11 Paracetamol Infusion
(Ifimol IV)
Each ml contains:
Paracetamol-10mg
(Paracetamol Infusion -1% w/v)
1 ml M/s J.B. Chemicals & Pharmaceuticals Ltd. 2.06
12 Atorvastatin Calcium
Tablet
(Atorvakind 20)
Each film coated tablet contains:
Atorvastatin Calcium eq. to
Atorvastatin-20mg
1 Tablet M/s Innova Captab & M/s Gem Mankind

 

11.00
13 Atorvastatin Calcium
Tablet
(Atorvakind 20)
Each film coated tablet contains:
Atorvastatin Calcium eq. to
Atorvastatin-20mg
1 Tablet M/s Mankind Pharma Ltd. & M/s Gem Mankind 11.00
14 Losartan Potassium+
Chlorthalidone Tablet
Each film coated tablet contains:
Losartan Potassium-50mg
Chlorthalidone-6.25mg
1 Tablet M/s Cadila Pharmaceuticals Ltd. 4.50
15 Olmesartan Medoxomil +Hydrochlorothiazide Tablet
(Olminorm-H)
Each film coated tablet contains:
Olmesartan Medoxomil 40mg
Hydrochlorothiazide-12.5mg
1 Tablet M/s Floreat Medica Pvt. Ltd. & M/s Indu Drugs Pvt. Ltd. 12.60
16 Tramadol HCl Tablet
(Caybutl SR)
Each film coated tablet contains:
Tramadol HCl-100mg
(in a controlled release system)
1 Tablet M/s Jagsonpal Pharmaceuticals Ltd.

 

12.00
17 Cefixime trihydrate +
Ofloxacin Tablet
(ODICEF OF)
Each film coated tablet contains:
Cefixime as trihydrate eq. to anhydrous Cefixime 200mg
Ofloxacin 200mg
1 Tablet M/s Innova Captab Pvt. Ltd.& M/s Galpha Lab. Ltd. 9.86
18 Clobetasol + Neomycin + Miconazole Cream Each gm contains:
Clobetasol Propionate-0.05% w/w
Neomycin Sulphate-0.5% w/w
Miconazole Nitrate-2.00% w/w
1 Gram M/s Apex Lab. Pvt. Ltd. 2.27
19 Azithromycin Oral Suspension Each 5ml contains:
Azithromycin-200mg
1 ml M/s Cadila Pharmaceuticals Ltd. 2.68
20 Azithromycin Suspension
(ATM Junior)
Each ml contains:
Azithromycin (as dihydrate) eq. to Azithromycin anhydrous-40mg
1 ml M/s Indoco Remedies Ltd. 2.68

 

21 Glimepiride+Voglibose
+ Metformin Tablet
(XMET- Trio 500/0.2/1)
Each uncoated bilayered tablet contains:
Glimepiride-1mg,
Voglibose-0.2mg,
Metformin Hydrochloride-500mg (as sustained release form)
10’s Tablets M/s Windlas Biotech Ltd.& M/s Glenmark Pharmaceuticals Ltd. 71.43
22 Glimepiride+Voglibose
+ Metformin Tablet
(XMET- Trio 500/0.2/2)
Each uncoated bilayered tablet contains:
Glimepiride-2mg,
Voglibose-0.2mg,
Metformin Hydrochloride-500mg (as sustained release form)
10’s Tablets M/s Windlas Biotech Ltd.& M/s Glenmark Pharmaceuticals Ltd. 90.48
23 Pantoprazole sodium+ Levosulpiride Capsule
(NICOPENTA LSR)
Each hard gelatine capsule contains:
Pantoprazole sodium sesquihydrate eq. to Pantoprazole (as enteric coated pellets)–40mg
Levosulpiride (as sustained release pellets) – 75mg
1 Capsule M/s Theon Pharmaceuticals Ltd. & M/s Abbott Healthcare Pvt. Ltd. 8.00
24 Halobetasol Propionate and Salicylic Acid Ointment Each gm contains:
Halobetasol Propionate-0.05% w/w
Salicylic Acid-6% w/w
1 Gram M/s Apex Lab. Pvt. Ltd. 9.99
25 Hyoscine Butyl Bromide + Paracetamol  Tablet

(Buscogast Plus)

Each film coated tablet contains:
Hyoscine Butyl Bromide-10mg
Paracetamol-325mg
1 Tablet M/s Kemwell Biopharma Pvt. Ltd. & M/s Boehringer Ingelheim India Pvt. Ltd. 3.76
26 Ondansetron Orally Disintegrating Strips 4 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-4mg
1 Strip M/s Nu Therapeutics Pvt. Ltd. & M/s Leads Pharma 9.11
27 Ondansetron Orally Disintegrating Strips 4 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-4mg
1 Strip M/s Nu Therapeutics Pvt. Ltd. & M/s Delvin Formulation Pvt. Ltd. 9.11

 

 

28 Ondansetron Orally Disintegrating Strips 4 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-4mg
1 Strip M/s Nu Therapeutics Pvt. Ltd. & M/s Mankind Pharma Ltd. 9.11
29 Ondansetron Orally Disintegrating Strips 4 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-4mg
1 Strip M/s Nu Therapeutics Pvt. Ltd. 9.11
30 Ondansetron Orally Disintegrating Strips 4 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-4mg
1 Strip M/s Zim Lab. Ltd. 9.11
31 Ondansetron Orally Disintegrating Strips 8 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-8mg
1 Strip M/s Nu Therapeutics Pvt. Ltd. & M/s Mankind Pharma 14.14
32 Ondansetron Orally Disintegrating Strips 8 mg Each Orally Disintegrating strip contains:
Ondansetron HCl eq. to Ondansetron-8mg
1 Strip M/s Nu Therapeutics Pvt 14.14
33 Mecobalamin+
Pyridoxine HCl+ Nicotinamide+D-Panthenol +Benzyl Alcohol Injection(Meganeuron Forte)
Each 2ml contains:
Mecobalamin 1000mcg
Pyridoxine HCl-100mg
Nicotinamide-100mgD-Panthenol-50mg Benzyl Alcohol
(as preservative)-0.9% and water for injection
Each Pack M/s Aristo Pharmaceuticals Pvt. Ltd. 26.50
34 Lipid Based Amphotericin B Gel
Tube
Each gm contains Amphotericin B-1mg 15gm Tube M/s Intas Pharmaceuticals Limited 200.00
35 Diclofenac Pottasium+
Chlorzoxazone Tablet
Each film coated tablet contains
Diclofenac Pottasium-50mg
Chlorzoxazone-500mg
1 Tablet M/s Windlas Biotech Limited and M/s Magnet Labs Pvt. Ltd. 6.50

 

 

36 Azithromycin + Dexamethosone Phosphate Eye Drops 3ml Vial :-

Each ml contains Azithromycin Dihydrate eq. to Azithromycin (anhydrous)-10mg/ml
Dexamethasone Sodium Phosphate eq. to

Dexamethasone Phosphate-1mg/ml Benzalkonium Chloride-(0.01%W/v)

Each Pack M/s Ajanta Pharma Ltd. 76.02
37 Paracetamol+
Phenylephrine HCl+
Caffeine+
Diphenhydramine HCl Tablet
(SUDIN Cold)
Each uncoated tablet contains:
Paracetamol-500mg, Phenylephrine HCl-5mg Caffeine(anhydrous)-30mg
Diphenhydramine HCl-25mg
1 Tablet M/s Embiotic Laboratories Ltd.

and M/s. Group Pharmaceuticals (P) Ltd.

3.30
38 Teneligliptin Hydrobromide Hydrate+ Metformin

Hydrochloride Tablet

Each uncoated bilayer tablet contains:

Teneligliptin Hydrobromide Hydrate equivalent to Teneligliptin 20mg
Metformin Hydrochloride-500mg

(as extended release)

1 Tablet M/s Glenmark Pharmaceuticals Ltd. 17.61

 

Note :

 

(a)       The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove.

(b)       The manufacturers may add local taxes only if they have paid actually or is payable to the Government on the retail price mentioned in column (5) of the above said table.

(c)       The retail price for a pack of the aforesaid formulations shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.

(d)       The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(e)       The concerned manufacturers of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of Schedule-II of the DPCO, 2013. Manufacturers, in case intending to discontinue above said formulation, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f)        In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g)       Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

 

PN/158/26/2016/F                                                   F. No. 8(26)/2016/D.P./NPPA-Div.-II

 

 

(BALJIT SINGH)

Assistant Director

 

 

 

 

63 Comments

  • Ersağ sitesi üzerinden ürün almak için öncelikle sponsor bulmanız gerekmektedir. Bu site sayesinde sponsorunuz olarak sizin kaydınızı yapıp üye numarası ve şifrenizi tarafınıza SMS atarak sizi üye yapmaktadır. Böylelikle 100 TL ve üzeri alışveriş yaptığıızda ömür boyunca ersağ üyesi olmuş olacaksınız.

  • Woah! I’m really enjoying the template/theme of this blog.
    It’s simple, yet effective. A lot of times it’s very hard to get that
    “perfect balance” between user friendliness and appearance.
    I must say you’ve done a fantastic job with this. Additionally, the blog loads very quick
    for me on Internet explorer. Excellent Blog!

  • Your article seems to suggest that introverts struggle with leadership roles “put in a position to lead or instruct can send us into a panic” – I actually find that quite offensive. Introverts are not necessarily bad presenters, leaders or instructors, likewise, being an extrovert does not make you good at those things.

  • When I originally commented I clicked the “Notify me when new comments are added”
    checkbox and now each time a comment is added I get three emails with the
    same comment. Is there any way you can remove me from that
    service? Appreciate it!

  • Thanks for the marvelous posting! I certainly enjoyed reading it,
    you are a great author.I will always bookmark your blog and
    will often come back sometime soon. I want to encourage continue
    your great posts, have a nice day!

  • A web site is an important business tool — and every business uses its site differently.
    Some use it to generate instant revenue through ecommerce sales while others use it to generate leads, telephone calls
    or physical location visits. There’s one thing that every business wants to accomplish having its website: leveraging it to generate more growth.
    There are numerous ways to improve your leads, sales and revenue without
    buying a complete redesign and rebuild. Here are 10 hacks that you should consider trying — while simple, they could
    potentially help your business grow significantly.
    1. Execute a conversion audit. Are you positive your
    website is made to convert traffic? The fact remains, lots of web
    design companies are great at creating appealing websites, however they aren’t conversion rate experts.

    Having a full-blown conversion audit performed is well worth the little out-of-pocket expense.
    Related: 5 Tools to Help You Audit Your Web Content If you can identify problems and make changes to improve them just before launching marketing campaigns it will certainly reduce
    wasted advertising spend and provide you with a stronger base to start with

  • May I just say what a comfort to uncover an individual who genuinely knows what they
    are talking about on the internet. You definitely realize how
    to bring a problem to light and make it important. A lot more
    people should look at this and understand this side
    of the story. It’s surprising you are not more popular given that you most certainly possess the gift.

  • Hmm is anyone else encountering problems with the images on this blog loading?
    I’m trying to determine if its a problem on my end or if it’s the blog.
    Any suggestions would be greatly appreciated.

  • I think this is one of the most important
    info for me. And i’m satisfied studying your
    article. However should statement on few general things, The site taste is great, the articles is
    truly great : D. Just right job, cheers

  • I have been surfing on-line more than three hours
    nowadays, yet I by no means found any attention-grabbing article like yours.

    It’s beautiful price enough for me. In my opinion,
    if all site owners and bloggers made excellent content material as you probably
    did, the internet will probably be much more helpful than ever before.

  • Its such as you read my mind! You seem to know a lot about this,
    such as you wrote the book in it or something. I feel that you just could do with some p.c.
    to power the message home a little bit, but other than that, that is wonderful blog.
    A great read. I will certainly be back.

  • Do you mind if I quote a few of your posts as long as
    I provide credit and sources back to your website?

    My blog site is in the exact same niche as yours and
    my users would genuinely benefit from a lot of the information you present here.

    Please let me know if this okay with you. Thanks a lot!

  • “We’ve got to build to a different one crescendo, cheri,”
    he said. “And we all could have an ending which is to be as none before.”

    His smile was decadent, his eyes were stuffed with lust,
    along with the soft skin of his hard cock against my sex was having its intended effect.

    I became feeling a stronger arousal now as I felt his cock slide between my sensitive lips.

    I felt your head of his cock push agonizingly at the doorway of my pussy, and
    I needed him to thrust into me hard. Instead he retracted and
    slid his hardness back as much as my clit.

    I had been aching to get him inside, and I could tell that his need to push that wonderful hard cock inside me was growing.

    His moans grew to match mine, and I knew the impression of my wet pussy lips to the head of his cock was
    getting too much both for of us.

    “Enable the finale begin,” he stated, and then he slid the end of his cock inside me.

    The two of us gasped because held his cock there for any moment.
    I contracted my pussy to get him further inside, and
    that he threw his return in the sensation. Inch by
    excruciating inch he pushed his cock inside me, and each and every time
    I squeezed my pussy around him. His cock felt wonderful the way it filled me, but I desired all this inside me.

    I rolled to the side and rested my leg against his shoulder, and that he plunged his cock entirely in.

  • I wɑs wondering whether anybοdy has гead bout tһe Peaches and Screams giveaway ?
    Ӏ just wߋn Bubble Wrap Lingerdie Bikini ϳust bү liking tһeir Twitter рage and publishingg ⲟne
    оf their posts. Purportedly, tһey arе offering an unliited giveaway thіs fuⅼl month.

    I felt I woսld llet еverybody know ѕo that yߋu сan get уourself ѕome magnificent lingerie fօr Valentine’ѕ Ɗay.
    I wouⅼd ⅼike to win Golden Goddess Garter Slip annd Thong Нere is their Facebook ⲣage btw – https://www.facebook.com/peachesandscreamsuk/

  • Hello,

    AliDropship is offering now 15% off every custom
    store. There are three plan for alidropship custom store, the coupon code for different stores may be
    different some time, you only have to click on the given link for different plans.

    The only working 15 OFF each package:

    Basic – $44.85 Off

    Dropshipping business with AliExpress

    Ultimate $134.85 Off

    Dropshipping business with AliExpress

  • In search engines, the results presented to the user about the search results are selected to give the best answer to the relevant search result. In the same area, there are hundreds or even thousands of websites and these sites try to appear as high as possible in the index of search engines. For this purpose, the algorithms developed by the search engines learn about the sites by examining certain criteria. According to this information, they rank the sites in their index. In this phase, the sites are called as search engine optimization in order to make arrangements in their own platforms in accordance with these criteria. Although this is a manipulation, a site that has been tailored to the search engines’ criteria has already become the site that can offer the best information for the user, so both search engines, site owners and users are satisfied. Our company continues to develop its knowledge and experience gained through the New York SEO studies, as well as the innovations that are constantly changing.

    1 New York SEO Company
    1450 Broadway 3rd Floor, New York, NY 10018
    https://1newyorkseo.com

  • Good day! Would you mind if I share your blog with my facebook group?
    There’s a lot of folks that I think would really enjoy your content.

    Please let me know. Thank you

  • An outstanding share! I’ve just forwarded this onto a coworker who was
    doing a little homework on this. And he actually bought me dinner due to the fact that I stumbled upon it for him…
    lol. So let me reword this…. Thanks for the meal!! But yeah,
    thanx for spending some time to talk about
    this subject here on your site.

  • Hеllo! Iam іn the idst οf making an application for a freshly qualified associate lawyer position ᴡith Smkins
    LLP inn London Сan someone let mе knoѡ wһere exactly I cаn llocate thee careers web page fоr this law practice?
    The jjob listing on thе https://latestlawjobs.com does not provide ɑny links or additional details.
    I am еspecially іnterested in newly-qualified lawyer jobgs ɑs opposed tо training contracts.
    I qualified ƅy sitting thhe New york city bar test аnd after that undertook thee QLTS examination ѕo the training contract route dooes not
    apply t᧐ me. Мɑny thankѕ in advance!

  • Hello there! I could have sworn I’ve been to this site before but after browsing through some of the post I realized it’s new to me.
    Nonetheless, I’m definitely delighted I found it and I’ll be bookmarking and checking back often!

  • Ꮋi еverybody! I am the advertising business manager аt WOWITLOVEITHAVEIT.
    Thank yоu foг alⅼ your thouɡhts andd suggestions oveг the last yeɑr.
    I can ceгtainly confirm tһat our USΑ Business Leads
    іs now օn sale. Oᥙr B2B DATA encompass in excess օf 10,000
    niches and micrο-niches including Envelopes B2В Database,
    Cable Installation Busness Leads , Industrial Tyres Β2B Email Marketing, Eаrly
    Careers – Attraction Β2B Marketing List and Battery Manufacturers & Suppliers В2B Mailing List Eacһ
    of our Business Sales Leqds inclսde thе business phone numbеr, internet site,е-mail, address, social
    networking sites hyperlinks аnd sߋ much more. We һave alгeady tremendously decreased tһе price of ouг B2В
    Compaies You аre abⅼe to maкe usee of oᥙr International Sales Leads fⲟr e-mail аs weⅼl as newsletter marketing, tele
    sales, social media marketing, website contact fօrm submisxions
    аnd even more. In thе near future, wе will bе publishing ᧐ur cutting edge email
    extractor сalled Yoggy’s Money Vault Search Engine Scraper
    aand Web mail Extractor tо allow you to extrct your own B2В leads!
    I reaⅼly hope the ɑbove answers all of yyour queries.

    Do not hesitate tto ᏢM me rіght heгe or respond t᧐
    thіs update!

  • Нi, Ι am tthe promotion ɑnd marketing admin ɑt Peaches
    and Screams. We ɑre currently havіng a go att to delve int᧐ the vape wholesale market.
    Ꭰoes anybоdy at all herre ossess any experience ԝith the vwpe industry
    оr B2B lead generation? We aгe very much predisposed tⲟ invest in tһe Global Vape Shop Database, Vape Company
    Е-Mail List ɑnd Yoggy’s Money Vaupt Search Engine Scraper in orⅾeг
    tօ produce ouг vеry own B2B leads. Does anyone here
    havе any kind oof expertise with аny of the ab᧐ѵe advertising ɑnd marketing tools?
    Ꮃould love to listen to your ideas ɑnd testimonials prior
    to committing myѕelf to the purchase. Lіkewise, I woukd considerably appreciatе any recomendations for
    assisting us t᧐ grow ourr vape wholesale operation. Ꭲhanks

  • Wow! This blog looks just like my old one! It’s on a totally different subject but it has pretty much the
    same page layout and design. Outstanding choice of colors!

  • Hi, i think that i saw you visited my blog so i came to “return the favor”.I am attempting
    to find things to enhance my web site!I suppose its ok
    to use some of your ideas!!

  • It is the best time to make a few plans for the future and it is time to be happy.

    I have read this submit and if I could I wish to recommend you some interesting things or tips.
    Perhaps you could write subsequent articles relating
    to this article. I wish to learn even more issues about it!

  • Its such as you learn my thoughts! You appear to grasp so much approximately this,
    such as you wrote the e-book in it or something.
    I believe that you simply can do with a few percent to force the message house a little bit, however instead of that, this
    is great blog. An excellent read. I’ll certainly
    be back.

  • Hiya very cool web site!! Man .. Excellent .. Amazing ..
    I will bookmark your web site and take the feeds additionally?

    I’m glad to search out a lot of helpful info right here within the publish, we’d like develop more
    techniques on this regard, thanks for sharing. . . . . .

  • It’s actually a nice and helpful piece of information. I am happy that you
    shared this helpful info with us. Please keep us up to date
    like this. Thanks for sharing.

  • Excellent post however , I was wanting to know if you could write a
    litte more on this topic? I’d be very grateful if you could elaborate a little bit more.

    Kudos!

Leave a Reply

Your email address will not be published.